FDA Approves QINLOCK (ripretinib) by Deciphera for 4L GIST Patients
The FDA approved QINLOCKTM (ripretinib) for the treatment of adults with advanced gastrointestinal stromal tumor (GIST) who have received 3 or more prior treatments for their GIST.
LRG Webcast Series: GIST, TKI Treatment & Effects on Memory
This discussion reviewed CRCI in general, and how a person who is being treated for GIST could be affected. We also talked about strategies that can help ameliorate CRCI, new research on CRCI and GIST. we also gave advice on how cancer survivors can best cope with and care for themselves during this unusual global health event.
Blueprint Medicines Does Not Receive Approval from FDA for Avapritinib for Treatment of 4L GIST
Blueprint Medicines Does Not Receive Approval from FDA for Avapritinib for Treatment of 4L GIST.
Life Raft Group Contributes Abstracts for ASCO
Although the ASCO (American Society for Clinical Oncology) will be a virtual meeting this year, The Life Raft Group continues to be at the forefront in collaborating in efforts to improve treatment for cancer patients. This year, two important abstracts will be presented online that illustrate these efforts.
Salud con Datos Produces Unique Analysis of Chilean & Mexican Patient Registries
This study is the result of a collaborative effort between Chile and Mexico, called Salud con Datos that sought to determine GIST prevalence, patients’ clinical characteristics and survival rates. Our report is the largest of its kind in Latin America.
NCCN Guidelines for GIST for Patients
The LRG has been granted permission from the NCCN to share the most recent NCCN Guidelines for Patients® with soft tissue sarcoma, most specifically the section on GIST, which the LRG has endorsed.
Sarcoma & COVID-19: Your Questions Answered
This webinar, Sarcoma & COVID-19: Your Questions Answered, produced by the Sarcoma Alliance, originally aired on May 2, 2020 and is available here for viewing. Hear advice from GIST Specialists on this health epidemic and how it affects GIST patients.
Dr. Gina D’Amato, GIST Specialist, Talks Advances in Sarcoma
In a recent post by Oncology Nursing News, Dr. Gina D'Amato, associate professor and assistant director of Clinical Research at Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the evolution of treatment in sarcoma, the use of NGS, and predictive and prognostic biomarkers under investigation in the space.
Blueprint Medicines Presents Cost of Testing Poster
Blueprint Medicines presented a poster titled “The Cost Impact of Increased Molecular Testing Rates for the Treatment of Patients with Gastrointestinal Stromal Tumors” at the annual meeting of the AMCP.
Science Forum Convened to Better Understand the State of GIST Research
As research regarding GIST and other relevant topics is extensive and dynamic, consensus among the Real World Evidence Team was that it would be a good idea to convene a group tasked with monitoring and assessing this research. Recently the LRG held its inaugural virtual meeting of the newly formed LRG Science Forum.